The sudden departure of Peter Marks, MD, from the FDA has prompted a chorus of criticism and despair from industry leaders and trade organizations.

BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by ...

LTR Pharma's SPONTAN nasal spray development pathway has reached another major milestone as it works toward US market entry. ...

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their ...

According to the Annenberg Space for Photography, Joel "served as a combat photographer during World War II, and several ...

Many recalls come as a result of product mislabeling, safety issues or contamination. Here are six recalls in particular that ...

Zaarah Herbals’ Rasayan Churan, Gurmar Powder, Vasaka Powder, and Bhringraj Powder recalled in four states due to potential ...

Dr. Peter Marks, who has overseen the FDA’s vaccine program since 2016, has resigned over Robert F. Kennedy Jr.’s ...

Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...